Skip to main content

Advertisement

SpringerLink
Log in

How Improved Local-Regional Therapy Impacts Survival

  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Findings from the 2005 Early Breast Cancer Trialists Collaborative Group overview of the effects of more extensive local therapy on breast cancer survival provide strong evidence supporting a causal link between local-regional cancer control and subsequent breast cancer survival. This article reviews the evidence supporting this link and discusses both the conditions that must be met for improved local-regional therapy to confer a survival benefit and the potential magnitude of the survival benefit from improved local-regional therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Horner MJ, Ries LA, Krapcho M, et al. (eds): SEER Cancer Statistics Review 1975–2006, National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2006/. Accessed December 31, 2009.

  2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2005, 365:1687–1717.

    Article  CAS  Google Scholar 

  3. Goldhirsch A, Ingle JN, Gelber RD, et al.: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319–1329.

    Article  CAS  PubMed  Google Scholar 

  4. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) Breast Cancer (Version 2.2010). © 2010 National Comprehensive Cancer Network, Inc. Available at: http://www.NCCN.org. Accessed March 23, 2010.

  5. Humphrey LL, Helfand M, Chan BK, Woolf SH: Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137:347–360.

    PubMed  Google Scholar 

  6. Berry DA, Cronin KA, Plevritis SK, et al.: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784–1792.

    Article  CAS  PubMed  Google Scholar 

  7. Fisher B, Jeong JH, Anderson S, et al.: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347:567–575.

    Article  PubMed  Google Scholar 

  8. Fisher B, Anderson S, Bryant J, et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002, 347:1233–1241.

    Article  PubMed  Google Scholar 

  9. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000, 355:1757–1770.

    Article  Google Scholar 

  10. Cuzick J, Stewart H, Rutqvist L, et al.: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994, 12:447–453.

    CAS  PubMed  Google Scholar 

  11. Ragaz J, Jackson SM, Le N, et al.: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997, 337:956–962.

    Article  CAS  PubMed  Google Scholar 

  12. Ragaz J, Olivotto IA, Spinelli JJ, et al.: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005, 97:116–126.

    PubMed  Google Scholar 

  13. Overgaard M, Hansen PS, Overgaard J, et al.: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997, 337:949–955.

    Article  CAS  PubMed  Google Scholar 

  14. Overgaard M, Jensen MB, Overgaard J, et al.: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999, 353:1641–1648.

    Article  CAS  PubMed  Google Scholar 

  15. Clarke M, Collins R, Darby S, et al.: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087–2106.

    CAS  PubMed  Google Scholar 

  16. Duric VM, Butow PN, Sharpe L, et al.: Psychosocial factors and patients’ preferences for adjuvant chemotherapy in early breast cancer. Psychooncology 2007, 16:48–59.

    Article  PubMed  Google Scholar 

  17. Duric VM, Stockler MR, Heritier S, et al.: Patients’ preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol 2005, 16:1786–1794.

    Article  CAS  PubMed  Google Scholar 

  18. Morrison JM, Howell A, Kelly KA, et al.: West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. II. Patients without involved axillary lymph nodes. Br J Cancer 1989, 60:919–924.

    CAS  PubMed  Google Scholar 

  19. Mansour EG, Eudey L, Tormey DC, et al.: Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr 1992, 11:97–104.

    PubMed  Google Scholar 

  20. Fisher B, Fisher ER, Redmond C: Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 1986, 4:929–941.

    CAS  PubMed  Google Scholar 

  21. Taylor SGt, Knuiman MW, Sleeper LA, et al.: Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol 1989, 7:879–889.

    PubMed  Google Scholar 

  22. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659–1672.

    Article  CAS  PubMed  Google Scholar 

  23. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673–1684.

    Article  CAS  PubMed  Google Scholar 

  24. Giordano SH, Kuo YF, Freeman JL, et al.: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005, 97:419–424.

    Article  PubMed  Google Scholar 

  25. •• Kyndi M, Overgaard M, Nielsen HM, et al.: High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol 2009, 90:74–79. This subgroup analysis of the Danish 82b and 82c trials evaluated the relationship between 5-year reduction in local recurrence and 15-year improvement in breast cancer survival in multiple prognostic groups. Improvement in survival for each reduction in local recurrence varied across prognostic groups, suggesting the proportional benefit of improved local control on survival may vary across subgroups of breast cancer patients.

    Article  PubMed  Google Scholar 

  26. Perou CM, Sorlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 2000, 406:747–752.

    Article  CAS  PubMed  Google Scholar 

  27. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869–10874.

    Article  CAS  PubMed  Google Scholar 

  28. Kyndi M, Sorensen FB, Knudsen H, et al.: Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:1419–1426.

    Article  CAS  PubMed  Google Scholar 

  29. Nguyen PL, Taghian AG, Katz MS, et al.: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008, 26:2373–2378.

    Article  PubMed  Google Scholar 

  30. Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817–2826.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1202, Houston, TX, 77030, USA

    Karen E. Hoffman & Thomas A. Buchholz

Authors
  1. Karen E. Hoffman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas A. Buchholz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen E. Hoffman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoffman, K.E., Buchholz, T.A. How Improved Local-Regional Therapy Impacts Survival. Curr Breast Cancer Rep 2, 83–89 (2010). https://doi.org/10.1007/s12609-010-0014-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-010-0014-4

Keywords

Search

Navigation